Small differences were noted in older versus younger patients in adverse events ( higher rates of depression , insomnia , and rash in older EFV-treated patients ) , laboratory abnormalities ( increased low-density lipoprotein cholesterol and hyperglycemia in older EFV-treated patients and increased amylase in older patients across treatments ) , bone mineral density ( larger decreases in older patients across treatments ) , and progression to severe vitamin D deficiency ( greater in older versus younger EFV-treated patients ) .